Full-Time

Head of Toxicology Innovation

Posted on 5/9/2026

Deadline 6/22/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$232.5k - $335.8k/yr

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Science
Machine Learning
Biochemistry
Pharmacology
Requirements
  • PhD in Toxicology, Pharmacology, Biochemistry, Computational Biology, or a closely related discipline
  • Minimum 15 years of progressive experience in toxicology within the pharmaceutical or biotechnology industry, with a demonstrated track record of scientific leadership and innovation
  • Deep expertise in preclinical safety assessment across multiple toxicological domains
  • Proven experience leading or significantly contributing to the development and application of AI/ML models or computational approaches in a safety context
  • Demonstrated experience with novel in vitro technologies and their application to mechanistic toxicology investigations
  • Established track record of leading and developing high-performing teams
  • Experience engaging with regulatory agencies and contributing to regulatory strategy
  • Strong scientific publication record and/or patent portfolio
  • International travel to Sanofi sites in France, the United States, and Germany, estimated travel 20% of working time
Responsibilities
  • Define and champion the long-term vision and roadmap for toxicology innovation, aligning with Sanofi's broader R&D digital transformation strategy and preclinical safety objectives
  • Identify, evaluate, and prioritize emerging technologies, methodologies, and scientific advances with the objective to enhance safety assessment and reduce drug attrition
  • Serve as the organizational authority and thought leader on the application of new approach methodologies (NAMs), digital tools, and investigative science in toxicology
  • Represent Sanofi in external scientific forums, regulatory discussions, industry consortia, and academic partnerships to advance the field and position Sanofi as an innovation leader in toxicology
  • Lead the development, validation, and deployment of AI and machine learning models for the prediction of safety liabilities, including target organ toxicity, genotoxicity, cardiotoxicity, and other key endpoints
  • Drive the build-out of computational platforms, predictive modeling pipelines, and data science capabilities in support of Global Preclinical Safety
  • Establish best practices and governance frameworks for the responsible use of AI/ML tools in regulatory-relevant safety assessment
  • Drive integration of predictive models into early drug discovery workflows to enable proactive safety-by-design decision-making
  • Direct the scientific strategy and operations of laboratories in France and the United States, ensuring delivery of high-quality mechanistic insights that inform drug development decisions
  • Champion the development and qualification of novel in vitro models — including organoids, microphysiological systems (MPS/organ-on-chip), and advanced cell culture platforms — to investigate mechanisms of toxicity and understand human relevance
  • Oversee the translation of mechanistic findings into actionable safety strategies, supporting candidate progression, risk mitigation, and regulatory submissions
  • Ensure laboratory operations meet the highest standards of scientific rigor, quality, and compliance across all sites
  • Drive cultural and operational transformation within the toxicology function, embedding innovation, agility, and data-driven decision making as core ways of working
  • Develop and implement frameworks for knowledge management, data sharing, and cross-site scientific collaboration across France, the US, and Germany
  • Identify opportunities to streamline and modernize toxicology workflows through automation, digitization, and the adoption of fit-for-purpose technologies
  • Benchmark Sanofi's toxicology innovation capabilities against industry peers and academic leaders, identifying gaps and opportunities for advancement
  • Engage proactively with regulatory agencies (FDA, EMA, and others) to advance the acceptance of novel methodologies and computational approaches in safety assessment
  • Contribute to the development of regulatory submissions, scientific briefing documents, and responses to agency queries related to innovative toxicology approaches
  • Build and maintain strategic partnerships with academic institutions, technology companies, and industry consortia to accelerate innovation and share pre-competitive knowledge
  • Provide direct leadership, mentorship, and performance management to a global team of scientists, computational toxicologists, and digital specialists across France, the US, and Germany
  • Build and sustain a high-performing, inclusive, and diverse team culture that encourages scientific curiosity, bold thinking, and cross-functional collaboration
  • Manage resource allocation, budget planning, and headcount strategy across all sites under remit
  • Develop talent pipelines and succession plans to ensure long-term organizational capability and resilience
  • Foster a psychologically safe environment where innovation is encouraged, and calculated scientific risk-taking is supported
  • Partner with site heads and functional leaders to ensure seamless integration of global and local priorities
Desired Qualifications
  • Experience with global matrix organization across multiple countries and cultures
  • Familiarity with regulatory frameworks governing NAMs and computational tools in safety assessment
  • Experience with microphysiological systems, organoid technologies, or other advanced human-relevant in vitro platforms
  • Prior experience managing multi-site laboratory operations and/or digital/data science teams
  • Established network within the toxicology innovation ecosystem (academia, regulatory, industry consortia)
  • Proficiency in or working knowledge of data science tools and programming environments (e.g., Python, R) relevant to toxicological modeling

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharma launches sales surged 49.6% to €1.2B in Q1 2026 from Ayvakit and ALTUVIIIO.
  • Dupixent generated €4.2B in Q1 2026 across nine indications, driving 13.6% sales growth.
  • Analysts project 16.4% undervaluation with fair value €95.53 versus €79.82 share price.

What critics are saying

  • Dupixent patents expire 2031, enabling Mylan and Teva generics to erode €4.2B quarterly sales.
  • Regeneron reimbursements drop €400M in 2026, slashing amlitelimab phase 3 funding.
  • GSK Arexvy captures 60% RSV market share, halving Beyfortus €284M Q1 sales by 2027.

What makes Sanofi unique

  • Venglustat crosses blood-brain barrier as oral GCSi for GD3 neurological symptoms.
  • LEAP2MONO phase 3 trial superior to ERT on neurological endpoints at week 52.
  • FDA Breakthrough Therapy designation for venglustat in GD3 on March 18, 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sanofi who can refer or advise you

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Novo Holdings
May 4th, 2026
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential.

Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

The Associated Press
Mar 31st, 2026
Sanofi's Rezurock approved in EU for chronic graft-versus-host disease treatment

The European Commission has granted conditional marketing authorisation for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 years and older weighing at least 40 kg. The treatment is approved for patients when other options provide limited benefit or have been exhausted. The approval follows a positive opinion from the European Medicines Agency and is based on the ROCKstar phase 2 study, which demonstrated a 74% overall response rate. Nearly half of chronic GVHD patients require third-line treatment, yet therapeutic options have remained limited in the EU. Rezurock is already approved in 20 countries, including the US, UK and Canada. More than 20,000 patients have been treated with the medicine since its first US approval in July 2021.

Yahoo Finance
Mar 30th, 2026
Bernstein initiates Sanofi with 'outperform' rating, $123 target price

Bernstein analyst Justin Smith has initiated coverage of Sanofi with an "Outperform" rating and a price target of €110, representing 37% upside from current levels. The analyst believes the French biopharmaceutical company's new chief executive will unlock shareholder value. Sanofi appointed Belén Garijo, former CEO of Germany's Merck KGaA, as its new chief executive in February. The 65-year-old Spanish executive will take charge in late April, replacing Paul Hudson after his six-year tenure. The company says Garijo will strengthen productivity, governance and innovation capacity in research and development. Sanofi shares have declined over 4.5% since the beginning of 2025. The stock trades at a forward price-to-earnings ratio of 9.26.